PainReform (NASDAQ:PRFX – Get Free Report) and Corcept Therapeutics (NASDAQ:CORT – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.
Earnings & Valuation
This table compares PainReform and Corcept Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| PainReform | $20,000.00 | 33.28 | -$5.02 million | ($736.66) | -0.00 |
| Corcept Therapeutics | $761.41 million | 11.25 | $99.65 million | $0.42 | 188.62 |
Corcept Therapeutics has higher revenue and earnings than PainReform. PainReform is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
PainReform has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500. Comparatively, Corcept Therapeutics has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for PainReform and Corcept Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| PainReform | 1 | 0 | 0 | 0 | 1.00 |
| Corcept Therapeutics | 1 | 2 | 5 | 0 | 2.50 |
Corcept Therapeutics has a consensus price target of $139.50, suggesting a potential upside of 76.09%. Given Corcept Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Corcept Therapeutics is more favorable than PainReform.
Profitability
This table compares PainReform and Corcept Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| PainReform | N/A | N/A | N/A |
| Corcept Therapeutics | 16.53% | 24.00% | 18.82% |
Institutional and Insider Ownership
37.3% of PainReform shares are owned by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are owned by institutional investors. 34.4% of PainReform shares are owned by insiders. Comparatively, 20.7% of Corcept Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Corcept Therapeutics beats PainReform on 11 of the 14 factors compared between the two stocks.
About PainReform
PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.
About Corcept Therapeutics
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.
Receive News & Ratings for PainReform Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PainReform and related companies with MarketBeat.com's FREE daily email newsletter.
